FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
07/28/2026
Back to search
Official data from USPTO
PNEOO
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
PNEOO
ST13
US500000079407300Class
1, 5, 40, 42
Filing
79407300
Registration
8226523
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
37
Latest update
07/28/2026
Trademark type
Word
Nice classes
1, 5, 40, 42
Filing date
08/08/2024
Registration date
04/28/2026
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
04/28/2026
Last transaction
07/28/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
26
Owner location
BE
Examiner
PEISECKI, MARK A
Law office
L50
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
PNEOO B.V.
Representatives
Cheryl L. Burbach Erise IP, P.A.
Technical classification
Nice Classes
Class 1Class 5Class 40Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Biological preparations for use in cell culturesother than for medical or veterinary purposesfor boosting cells in the immune system for improved therapies; biological preparations for use in cell culturesin the nature of genetically modified cells and vectors for scientific and research purposes; biological and chemical reagents in the nature of complexes of molecules for scientific research and for clinical and industrial use; proteins for use in scientific research; regulatory proteins in raw material for scientific research; the aforementioned goods solely related to respiratory and pulmonary diseasesincluding lung cancer
Class 5
Medicalbiologicalpharmaceutical preparations for the treatment of pulmonary diseases; veterinary preparations for petscattlelivestock for preventing and treating infectious diseasesmedical disordersdiseaseslung cancer; medicalbiologicalpharmaceutical preparations for preventing and treating infectious diseasesmedical disordersdiseaseslung cancer; medicalbiologicalpharmaceutical preparations for preventing and treating viralbacterialyeast infections; veterinary preparations for petscattlelivestock for preventing and treating viralbacterialyeast infections; medicalbiologicalpharmaceutical preparations for preventing and treating cancermetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disorders; veterinary preparations for petscattlelivestock for preventing and treating cancermetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disorders; vaccines; regulatory proteins for medical useprotein arrays for medical diagnosis purposesthe foregoing solely related to respiratory and pulmonary diseasesincluding lung cancer; pharmaceutical compounds being a component in pharmaceutical preparations for treating respiratory diseases; pharmaceutical preparations for the prevention of diseases of the respiratory system; diagnostic preparations for medical purposesthe foregoing solely related to respiratory and pulmonary diseasesincluding lung cancer; chemical diagnostic reagents for medical usethe foregoing solely related to respiratory and pulmonary diseasesincluding lung cancer
Class 40
Provision of informationadvice and consultancy services in the fields of cell therapygene editingprotein replacementantibodiesthe aforementioned services solely related to respiratory and pulmonary diseasesincluding lung cancer
Class 42
Medical research services for the treatment of various medical disorderscancerpulmonary diseasesrespiratory diseasesinfectious diseases; Scientific laboratory services; scientific research for medical purposes in the area of diseases; scientific research in the field of genetics and genetic engineering; genetic research for scientific research purposes; genetic mapping for scientific purposes; DNA screening for scientific research purposes; DNA analysis services for scientific research purposes; providing scientific research information in the field of medical disorders and their treatment; biotechnological research relating to enzymatic synthesis; toxicity testing for scientific research purposes; toxicity analysis for scientific research purposes; software as a service (SaaS) featuring artificial intelligence software for use in database management relating to the medical field; software as a service (SaaS) featuring software for use in data base management relating to the medical field; all of the aforementioned services solely related to respiratory and pulmonary diseasesincluding lung cancer
Publications
History of USPTO decisions and trademark events.
37 publications found
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
04/28/2026
R.PR
REGISTERED-PRINCIPAL REGISTER
04/28/2026
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
04/13/2026
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
04/13/2026
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
04/13/2026
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
04/13/2026
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
04/13/2026
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
04/09/2026
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
03/23/2026
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
03/23/2026
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/10/2026
PUBO
PUBLISHED FOR OPPOSITION
03/10/2026
GPNX
NOTIFICATION PROCESSED BY IB
03/05/2026
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/04/2026
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
02/18/2026
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
02/17/2026
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/10/2026
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/31/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/31/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/31/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
11/14/2025
RFNT
REFUSAL PROCESSED BY IB
11/07/2025
CNRT
NON-FINAL ACTION WRITTEN
10/09/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/08/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/08/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/08/2025
RFNT
REFUSAL PROCESSED BY IB
04/12/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
03/28/2025
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
03/27/2025
RFRR
REFUSAL PROCESSED BY MPU
03/27/2025
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
02/21/2025
CNRT
NON-FINAL ACTION WRITTEN
02/20/2025
DOCK
ASSIGNED TO EXAMINER
02/13/2025
MAFR
APPLICATION FILING RECEIPT MAILED
10/24/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/24/2024
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
10/24/2024
Continuous trademark protection
Get notified about every new filing that threatens PNEOO or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.